Innovation | Novartis United States of America

Media Release
Feb 11, 2020
Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review
Media Release
Jan 16, 2020
Public-Private Collaboration Commits to Accelerate Access to Health Services in Africa, Reaching 1.7 Million People
Media Release
Dec 11, 2019
Novartis announces FDA filing acceptance of Xolair® (omalizumab) for treatment of nasal polyps
Media Release
Mar 28, 2020
Novartis new analysis further showed durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment
Media Release
Jun 03, 2021
Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study
Media Release
Apr 06, 2022
FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)
Media Release
Mar 24, 2022
Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA-positive metastatic castration-resistant prostate cancer
Media Release
May 28, 2022
FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
Story
Jan 09, 2020
Sourcing innovation, strategically